Peptide TB500 (10mg) OxyPharma

Catalogue entry: Peptide TB500 OxyPharma. Labelled content: 10 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

TB-500 is a commercial and research label whose molecular meaning needs confirmation. In an analytical study by Ho and colleagues in 2012, tested material contained an acetylated thymosin beta-4 fragment. Full-length thymosin beta-4 is a different, 43-amino-acid peptide. The label alone does not tell you which material is present.

What the research measured

Research into full-length thymosin beta-4 includes topical wound and ophthalmic formulations. Guarnera and colleagues studied venous ulcers in 2010, while Sosne and colleagues reported dry-eye research. These studies do not establish the efficacy of an unknown TB-500 preparation for tendons, muscle or sporting recovery. The tissue, formulation and exact molecule all matter.

Sporting claims and limitations

Bodybuilding discussions often pair TB-500 with BPC-157 under a broad repair narrative. That pairing is not evidence of a clinically established combination. Thymosin alpha-1 is another distinct molecule despite the shared word thymosin. Neither a related name nor a plausible role in cell migration can guarantee faster injury healing or settle long-term safety.

Product identity and documentation

For this product, ask whether the batch specification defines a fragment or full-length sequence, its modifications and chemical form. The declared amount must be interpreted alongside that identity. Analytical method, lot traceability and composition are more useful than a generic peptide certificate. A full-length-peptide study cannot fill the identity gap of a differently labelled supplier vial.